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ABSTRACT 
Objective: The objective of the present study is the preparation of metronidazole (MZ) floating tablets that are designed to retain in the stomach for 
a long time for better eradication of Helicobacter Pylori (H. pylori), a main cause of peptic ulcer disease. 
Methods: Synthetic and natural polymers were studied for their floating potential in the presence of sodium bicarbonate, namely: hydroxypropyl 
methylcellulose (HPMC), carbopol 974P, sodium alginate {low and medium viscosity (LV & MV) grades}, locust gum and guar gum. Hardness, 
floating ability, release profiles and kinetics as well as DSC / FT-IR were studied.  
Results: Results of both DSC and FT-IR spectroscopy revealed that there was no interaction between the drug and any of the proposed polymers. 
Carbopol 974P based tablets showed an unacceptable floating lag time (2 h) and did not maintain good tablet integrity. All other formulas were able 
to float after few seconds and showed buoyancy for more than 24 h. Meanwhile, sustained profiles of MZ release were obtained. After 6 h the 
amount of MZ released were: 75.11 %, 61.26 %, 54.56 %, 54.25 % and 43.42 % from sodium alginate-LV, HPMC-K4M, guar gum, locust gum and 
sodium alginate-MV based tablets, respectively. Kinetically, among the 5 assessed models, the release pattern of MZ from the tablets fitted best to 
Zero order and Hixson & Crowell Cube-Root models. 
Conclusion: These stomach targeted dosage forms could maintain the minimum inhibitory concentration for sufficient time to allow for local 
eradication and thereby achieve better efficiency of therapy with improved patient compliance, reduced costs and minimized side effects caused by 
immediate release dosage forms. 
Keywords: Metronidazole, Floating tablets, HPMC-K4M, Alginates, Gums, Drug-polymer interaction, Release kinetics.  
 
INTRODUCTION 
Oral delivery of the drug is the most preferable route of drug 
delivery due to the ease of administration, patient compliance and 
flexibility in the formulations. Recent technological advancements 
have been made in controlled oral drug delivery systems by 
overcoming physiological difficulties, such as short gastric residence 
time (GRT) and highly variable gastric emptying time [1]. Gastric 
residence time is the major physiological constrain which is 
responsible for the reduction in efficacy of oral controlled release 
dosage forms. GRT considerably affects the bioavailability of 
pharmaceutical dosage forms [2].  
Variable and short gastric emptying time results in incomplete 
drug release from the oral controlled release dosage forms 
(OCRDF) which leads to diminished efficacy of the administered 
dose [3]. GRT is affected by both the fasting as well as fed states of 
the stomach. Gastric emptying studies revealed that the short GRT 
and unpredictable gastric emptying rate have altered the 
performance of OCRDF [4]. To improve the performance of OCRDF, 
scientists have discovered a new concept in drug delivery, that is, 
gastroretentive drug delivery systems (GRDDS). A GRDDS can be 
defined as a system which remains in the stomach for a sufficient 
time interval against all the physiological barriers, releasing the 
active moiety in a controlled manner, and finally becomes 
metabolized in the body [5].  
A GRDDS can be a useful tool in delivery of drugs that are primarily 
absorbed in the duodenum and upper jejunum or those that have an 
absorption window in the gastrointestinal tract (GIT) [6-8]. Such 
delivery system is appropriate for drugs which are locally active in 
the gastric mucosa, for example, antibiotic administration for 
Helicobacter pylori (H. pylori) eradication [9,10] and in the treatment 
of peptic ulcer and gastritis [11,12]. Drugs that are less soluble in or 
are degraded by the alkaline pH may get benefit by being 
incorporated in GRDDS for prolonged gastric retention and 
consequent improved oral bioavailability and therapeutic efficacy by 
possible reduction of dose size [13,14].  
Floating systems are more popular in comparison with the other 
described GRDDS [15-17] because they do not have any adverse 
effect on the motility of the GIT [18]. Floating drug delivery systems 
have lower density compared with gastric fluid which enables them 
to float over the surface of gastric fluid [19]. Drug release from the 
system takes place slowly at the required rate which results in 
reduced fluctuation in the plasma concentration along with 
increased GRT [20]. 
Hydrophilic polymers are actually one of the most used excipients to 
control drug delivery from an oral pharmaceutical dosage form 
including GRDDS and may be classified as either synthetic or natural. 
Carbopol 974P-NF is the oral pharmaceutical grade of the carbomers 
and is an example of polymers with highly crosslinked structure 
[21]. Carbopol and hydroxypropyl methylcellulose (HPMC-K4M), a 
semi-synthetic cellulose derivative, have been used by other authors 
to prepare MZ floating matrix tablets [22-25].  
In spite of the advent of many synthetic polymers, use of natural 
polymeric materials has gained a lot of importance during the 
last two decades in drug delivery field. Incorporation of natural 
polymers in various drug delivery systems seems to be an active 
area of research and development due to obvious advantages 
including being biocompatible, inexpensive and ready 
availability [26]. These polymers, particularly those with 
pronounced swelling properties have been frequently employed 
in the formulation of different gastroretentive products [27]. 
Drug delivery systems targeted to stomach which are based on 
the utilization of various natural polymer offer superiority over 
other systems. Moreover, these polymers are safe, nontoxic, 
capable of chemical modification and gel forming nature. Natural 
polymers which have been explored for their promising 
potential in stomach-specific drug delivery include alginates 
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[28], xanthan gum [29], chitosan [29], locust gum [30], guar gum 
[31,32], pectin, gellan gum, karaya gum, psyllium husk, starch, 
etc [33,34].  
In the last decade, the number of patients suffering from peptic ulcer 
and gastric cancer due to H. pylori infection has increased 
tremendously. H. pylori are spiral, gram-negative, microaerophilic 
rod-shaped bacteria with multiple flagella [35,36]. H. pylori which 
remains on the luminal surface of the gastric mucosa under mucous 
gel layer, is highly motile, and produces enzyme urease to alter the 
surrounding pH to protect itself from gastric acid [36]. The current 
therapy for the treatment of H. pylori involves use of proton pump 
inhibitors with antibiotics and has drawbacks like poor patient 
compliance and increased bacterial resistance due to higher multiple 
dosage of antibiotics [37,38].  
There could be one or several reasons for the failure of antibiotic 
therapy against H. pylori. Firstly, the organism resides in the mucus 
gel close to the acidic environment of the gastric fluid. Many 
antibacterial agents, such as penicillin and erythromycin, degrade 
rapidly in acidic medium. Secondly, the drug must diffuse into the 
mucus layer and the bacterial glycocalyx to furnish concentrations 
sufficient for antibacterial activity. For eradication of H. pylori in the 
stomach the concentrations of antibacterial agents reaching the site 
of infection from tablets or capsules might not be bactericidal 
against organisms located in the mucus layer and protected by the 
glycocalyx. Lastly, the contact time of antibacterial drugs with the 
organism needs to be sufficiently long for successful eradication of 
H. pylori from the gastric mucosa, that can be achieved through a 
GRDDS [39,40]. Delivering drug at the site of infection for a longer 
period of time is one of the approaches to improve the efficacy of 
antibiotic therapy [41,42]. Metronidazole (MZ) is an active adjunct 
in treatment of H. pylori [43] with the commonly reported side 
effects including anorexia, nausea, vomiting, and epigastric pain. 
Metallic taste, mouth dryness, probably caused by the presence of 
high concentrations of the drug in the saliva, and furring of the 
tongue are also reported [44]. Therefore, certain MZ floating 
systems were developed for better eradication of H. pylori, 
including: floating MZ tablets [22-25,45] and beads [28,46-50]. Such 
dosage forms for MZ would be beneficial in delivering higher 
concentrations of the antibacterial agent in the gastric mucosa 
where H. pylori resides ensuring better microorganism eradication. 
Furthermore, such treatment may lead to drug dose reduction which 
will be an additional valuable advantage [48]. 
In our previous work, the one year bench stability studies for the 
prepared MZ double layer floating tablets, containing PEO (M. W. 
8,000,000) in the gas generating layer and PEO (M. W. 900,000) in 
drug release layer, revealed a pronounced increase in MZ release 
rate, between fresh and stored tablets, with “ƒ2” value equal to 25.0. 
This means that the product was not stable upon storage [40]. These 
results directed us to search for other alternatives and the need for 
investigating other polymers (especially the natural ones) regarding 
their feasibility to be used as release retarding and floating agents 
for the preparation of MZ floating tablets of improved stability. 
The objective of the present study was to prepare MZ floating matrix 
tablets based on a hydrophilic polymer and a gas-former namely 
sodium bicarbonate (NaHCO3). Such tablets will help to achieve 
higher concentrations of the antibacterial agent in the gastric 
mucosa. The hydrophilic polymers used were either synthetic: 
Carbopol 974P-NF and HPMC (K4M), or natural: sodium alginate (Na 
alginate), guar gum and locust gum. The mechanism of release was 
elucidated to obtain a general kinetic model for drug release profile . 
The in vitro release and floatability studies for the prepared MZ 
tablet formulations were performed. The results will increase our 
understanding of the tablets' floatability and the release control 
from these types of matrices.  
MATERIALS AND METHODS  
Materials 
Metronidazole (MZ; Batch no. 10053 F090020, Exp. date 5/2014) 
was kindly supplied by EIPICO, Egypt. Hydroxypropyl 
methylcellulose [HPMC-K4M, the viscosity of 2 % water solution is 
4000 cps] was purchased from Aldrich, Germany. Sodium alginate 
(low and medium viscosity) and locust gum were purchased from 
Aldrich (Germany). Guar gum and carbopol 974P-NF were gifted 
from Novartis (Egypt). Sodium bicarbonate (NaHCO3) was from 
Kahira Pharm. (Egypt). Methanol (HPLC grade) was from Prolabo 
(France). Distilled water was used for all experiments (Milli RO plus 
10, Millipore, USA). All other reagents were of analytical grade. 
Methods 
Tablet preparation 
MZ tablets were prepared using a rate controlling polymer and a 
gas-generating excipient. Each formula contained 250 mg MZ, 20 % 
(w/w) of a single polymer as shown in Table 1 and sodium 
bicarbonate as the gas-generating agent. Locust gum and guar gum 
based formulas were uncompressible as such therefore; avicel was 
added to these two formulas to aid compression. All ingredients (for 
each formula) in their specified ratios (Table 1) were sieved through 
710 μm sieve (mesh number 25). Blending of all ingredients was 
carried out simultaneously using polyethylene bag [51], after which 
tablets were prepared from different blends by direct compression 
at 1.5-tons compression force (Single Punch Press Tablet Machine, 
Stokes- Merrill Model 511-7-A, USA). For such formulas, a round die 
(13 mm internal diameter) with flat-faced punches were employed 
to give round flat-surface tablets. 
  
Table 1: Composition of metronidazole floating tablets (250 mg/tablet). 
  Composition:% (w/w)/tablet 
  M1 M2 M3 M4 M5 M6 
HPMC-K4M 20 0 0 0 0 0 
Na alginate (medium viscosity) 0 20 0 0 0 0 
Na alginate (low viscosity) 0 0 20 0 0 0 
Locust Gum 0 0 0 20 0 0 
Guar Gum 0 0 0 0 20 0 
Carbopol 974P 0 0 0 0 0 20 
NaHCO3 10 10 10 20 20 10 
Avicel 0 0 0 20 20 0 
 
Characterization of the prepared tablets 
Physical parameters 
PTB (311E) 3 in 1 Hardness, Diameter and Thickness Tester (PTB 
311E Tablet Testing Instument, Pharma Test Apparatebau AG, 
Germany) was used for determination of thickness, diameter, 
weight, and hardness of the prepared tablets (mean of twenty 
tablets for each formula was calculated).  
Content uniformity 
Twenty tablets of each formula were weighed, grinded, and the 
weight equivalent to one tablet was transferred quantitatively into 
250 ml volumetric flask.  
About 100 ml dilute HCl (1 in 100) were added to each flask and 
then the flasks were shaken for 30 min using "temperature- 
controlled shaking water-bath (Lab-Line, USA)" at 37 °C. The volume 
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was then completed to the mark with dilute HCl (1 in 100) followed 
by mixing [52]. The solution was then filtered and appropriate 
dilutions were done to the filtrate using dilute HCl (1 in 100). The 
absorbance was then measured spectrophotometrically (UV-Visible 
spectrophotometer, Beckman, DU-650, USA) at the predetermined 
λmax at 277 nm for MZ.  
Determination of floating lag time and floating duration of the 
prepared tablets 
The time required for the tablets to emerge on the dissolution 
medium surface (floating lag time) and the time the tablets 
remained floating on the dissolution medium surface (floating 
duration) were inspected visually in 1L jacketed jar connected to 
Julabo circulator (F10-VC, Germany), filled with 400 ml 0.1 N HCl, pH 
1.2 [53], at 37 ± 0.5 °C [54]. The results were registered as an 
average of three repetitions. 
In vitro release studies 
These studies were carried out using the closed system of the 
flow-through cell, USP Apparatus 4, which is composed of Dissotest 
CE-6 equipped with a CY 7-50 piston pump (Sotax, Switzerland). 
Each tablet was placed into the large dissolution cell (22.6 mm 
diameter) according to the cell design shown in Fig.1. This design 
was chosen as it allowed for floating observations while studying the 
release profile. Built-in filtration system (0.7 μm Whatmann GF/F 
and GF/D glass micro-fiber filters, and glass wool) was used 
throughout the study. The dissolution medium was 900 ml 0.1N HCl 
(pH 1.2), which was filtered (on 0.45 μm filter), degassed and then 
pumped at a laminar flow rate of 16.0 ± 0.2 ml/min. Temperature of 
the dissolution medium was kept constant at 37 ± 0.5 °C. At 
predetermined time intervals, 10 ml samples were collected and 
replaced by the same volume of the fresh dissolution medium. 
Collected samples were then analyzed spectrophotometrically (UV-
Visible spectrophotometer, Beckman, DU-650, USA) for MZ content 
by measuring the absorbance at the corresponding λmax (277 nm) 
against 0.1N HCl (pH 1.2) as blank. Each formula was tested in 
triplicate for up to 6 h and the mean value was calculated.  
 
 
Fig. 1: Dissolution cell design used for the prepared floating 
tablets: laminar flow with free tablet position (glass beads 
filling the entry cone). 
 
Comparison between different release profiles 
The similarity factor (ƒ2), as proposed by Moore and Flanner [55] 
was calculated from the mean release data and used to compare 
between the different release profiles. ƒ2 is      given by Eq. (1): 
ƒ2 = 50 x log {[1+ (1/n) Σt=1n (Rt – Tt) 2] - 0.5 x 100} Eq. (1) 
Where, n is number of data time points collected during the in vitro 
release test, Rt and Tt are the cumulative release percentages 
released at the selected (n) time point of the two tested formulas. 
The ƒ2 value is a measure of the similarity between two dissolution 
curves and its value ranges from 0 and 100. A high ƒ2 value indicates 
high similarity between two release rate profiles. FDA suggests that 
two dissolution profiles are considered similar if the similarity 
factor ƒ2 is between 50 and 100 [55,56]. 
Kinetic study of drug release data 
In order to describe the kinetics of MZ release from the prepared 
sustained release tablets, various mathematical equations were 
applied; 
Zero-order Equation [57,58]: Qt = k0. t Eq. (2)  
First-order Equation [57-60]: ln (100 – Qt) = ln 100 – k1. t Eq. (3) 
Second-order Equation [58]: 1 / (100 – Qt) = k2. t Eq. (4)  
Higuchi model Equation [57,59,60]: Qt = kH. t1/2 Eq. (5) 
Hixson–Crowell model Equation [57,59,60]: (100 – Qt)1/3 = (100)1/3 – 
kHC. t Eq. (6) 
where, Qt is % drug release at time t; k0, k1, k2, kH, and kHC are release 
rate constants for zero-order, first-order, second-order, Higuchi 
square root of time model, and Hixson–Crowell cube root model 
equations [Eqs. (2-6)], respectively. MZ release data obtained was 
subjected to different drug release models in order to establish the 
drug release mechanism and kinetics. The criteria for selecting the 
most appropriate model was based on the best goodness of fit and 
the smallest sum of squared residuals (SSR) [61,62]. 
Physico-chemical interaction studies 
Differential scanning calorimetry (DSC) studies 
DSC was performed for pure MZ, pure polymers and crushed tablets 
of each batch to detect any possible chemical interactions between 
the drug and polymers and other excipients employed in tablet 
formulations. DSC thermograms were performed using an automatic 
thermal analyzer (DSC-50, Shimadzu, Japan). Sealed and holed 
aluminum pans heated in an atmosphere of nitrogen were used in 
the experiments for all samples and an empty pan, prepared in the 
same way was used as a reference. Samples of pure drug and 
powdered tablets of 5 mg each were weighted directly into the 
aluminum pans and the thermal analysis was carried out using 
heating ramp from 25 to 300 °C at 10 °C/min scale up rate. A 
nitrogen purge (20 ml/min) was maintained throughout the run.  
Fourier transform-infra red (FT-IR) analysis 
FT-IR spectra were obtained using Jasco FT-IR-6100 spectrometer 
(Jasco, Japan). The samples (pure MZ, pure polymers and crushed 
tablets of each batch) were previously ground and mixed thoroughly 
with potassium bromide, an infrared transparent matrix, at 1:5 
(sample:KBr) ratio, respectively. The KBr disks were prepared by 
compressing the powders at a pressure of 5 tons for 5 min in a 
hydraulic press. Scans were obtained at a resolution of 4 cm-1, from 
4000 cm-1 to 400 cm-1.  
RESULTS AND DISCUSSION  
Physical parameters of floating tablets 
Weight variation 
All the prepared floating tablets showed acceptable weight variation 
range. The average tablet weight for M1, M2, M3 and M6 ranged 
from 373.1 to 335.3 mg and from 654.3 to 590.6 mg for M4 and M5 
(cf. Table 1 for tablet composition). Not more than two tablets 
deviated from the average weight by more than 5.0 % (which is the 
percentage deviation allowed according to the British 
pharmacopoeia for uncoated and film-coated tablets weighing more 
than 250 mg), and none of the tablets deviated by more than twice 
that percentage [63].  
Thickness and diameter  
The prepared tablets showed good uniformity of thickness and 
diameter. The values of tablet thickness were in the range of 2.25 to 
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2.43 mm for M1, M2, M3 and M6 and from 4.26 - 4.33 mm for M4 
and M5. The average diameter ranged from 12.73 to 12.84 mm.  
Hardness 
Average tablet hardness was between 3.33 and 6.45 kP, except for 
Carbopol 974P based formula (M6) where the average tablet 
hardness was 24.6 kP.  
Content uniformity 
The drug concentration was not less than 92 % and did not exceed 
100 % of the labeled claim. This result indicated that all the 
prepared formulations complied with the limits of pharmacopoeia 
for content uniformity, i.e., the average percentage of drug content of 
all formulas was found to be within the range of 85 % and 115 % of 
the label claim [64].  
In vitro evaluation 
Floating lag time and floating duration 
The investigated gastric floating tablets consisted of NaHCO3 as a 
gas-forming agent dispersed in a hydrogel matrix. When the tablet 
reaches the stomach, carbon dioxide gas is liberated by the acidity of 
the gastric contents and is entrapped in the jellified hydrocolloid. A 
decrease in specific gravity causes the tablet to float on the test 
medium [54,65]. The extended residence time of drug in stomach 
could ensure more localized drug concentration which is useful for 
H. pylori eradication [25,66].  
The preformulation optimization studies of tablets prepared with 
plain polymers showed that 10 % NaHCO3 was required to achieve 
acceptable in vitro buoyancy. However, when avicel was added, to 
the tablets containing locust gum (M4) and guar gum (M5) in order 
to improve compression, NaHCO3 percent had to be raised to 20 % to 
improve floating properties. In both cases, further increase in the 
concentration of NaHCO3 did not show any remarkable 
improvement on floating behavior. Moreover, other researchers 
reported that when the amount of NaHCO3 was increased, a large 
amount of effervescence occurred, which in turn resulted in pore 
formation, these pores led to rapid hydration of the polymer matrix 
and thereby to rapid drug release [67]. 
Table 2 showed the floating lag time (FLT), which is considered as 
one of the factors influencing the behavior of the effervescent 
systems as well as the floating duration (FD). All tablet formulas 
(except for formula M6) showed an almost instantaneous flotation 
with a floating lag time of 1-2 s (SD < 0.01), good matrix integrity, 
and a prolonged floating duration of more than 24h. This suggests 
that the gel layers, formed by the investigated polymers, enabled 
efficient entrapment of the generated gas bubbles. The possible 
increase in tablet gas entrapment made it float on the test medium 
(0.1 N HCl) for this extended period of time, without the loss of 
tablet integrity [31,68]. 
 
Table 2: Summary of the results of floating lag time (FLT) and floating duration (FD) for the prepared MZ tablets 
Formula code Polymer used FLT (s) FD (h) Matrix integrity 
M1 HPMC-K4M 2 > 24  + 
M2 Na alginate, medium viscosity 1 > 24 + 
M3 Na alginate, low viscosity 1 > 24 + 
M4 Locust gum 1 > 24  + 
M5 Guar gum 1 > 24  + 
M6 Carbopol 974P 7200 > 24  - 
 (+) sign indicates good matrix integrity, (-) sign indicates loss of matrix integrity 
 
Among all polymers, Carbopol 974P based tablets, M6, showed an 
extreme delay of floating lag time (2 h) and did not maintain good 
tablet integrity as well, where the polymer swelled and diffused 
resulting in a very weak texture. These results were unexpected 
from the preliminary studies, done in our laboratory, for tablets 
prepared with plain Carbopol 974P and 10 % NaHCO3. These plain 
tablets were able to show acceptable in vitro buoyancy, with a mean 
FLT of 6 s and a FD of more than 24 h; meanwhile, good matrix 
integrity was maintained. Therefore, in this case carbopol might 
provide other gastroretentive mechanisms to maintain the GRDDS in 
the GIT but not a good candidate specifically, for incorporation of an 
amount of 250 mg MZ in GFDDS. Thus, this formula was excluded 
from further release studies.  
This negative effect, with another grade of carpobol (CP934), on the 
floating behavior was also reported by other researchers [69]. Their 
results demonstrated that incorporation of CP934 had an 
undesirable effect on the floating behavior of gastric floating calcium 
capsules. This was explained by a moisture isotherm of CP934, 
illustrating that CP934 had a high moisture absorption curve. This 
resulted in a dramatic increase in the density of the GFDDS, which in 
turn showed a corresponding decrease in the floating capacity of 
GFDDS [69].  
In vitro release studies 
Depending on the type of the investigated polymer in the current 
study, various drug release profiles were successfully tailored. 
Release profiles of the five selected tablet formulations, based on the 
results of the in vitro buoyancy studies, with acceptable floating 
properties were studied. Fig. 2 showed the influence of the polymer 
type on the release of MZ from the floating tablets in acidic medium. 
All tablet formulations were found to maintain good matrix integrity 
and MZ release retardation.  
The percentages of MZ released after 6 h (Q6h) from different 
polymers as well as the release similarity between HPMC-K4M and 
the natural polymers studied [alginates (MV & LV), gums (locust & 
guar)] are shown in Table 3. The results displayed showed that after 
6 h, 43 % (lowest drug release), 54.25 %, 54.56 %, 61.26 %, and 75 
% (highest drug release) of MZ were released from M2 (Na alginate - 
MV), M4 (locust gum), M5 (guar gum), M1 (HPMC-K4M) and M3 (Na 
alginate - LV), respectively. These polymers (except Na alginate - 
MV) could be used as an alternative to the widely used synthetic 
polymer HPMC - K4M for formulating floating tablets containing 250 
mg MZ. This will be advantageous as natural polymers are safer, 
nontoxic, capable of chemical modification and have gel forming 
nature. Moreover, they are biocompatible, inexpensive and readily 
available compared to synthetic polymers. However, the long - term 
stability of the product will be the key factor for product selection. 
Moreover, the similarity factor ƒ2 value between the tablets of the 
two grades of alginates (MV & LV) corresponding to formulas M2 
and M3 release curves was found to be 40, indicating that these two 
release curves are not similar [56]. These results revealed that 
different formulation variables, specifically in this case Na alginate 
viscosity grade, were crucial for MZ release from the prepared 
floating tablets. On the contrary, when the two release profiles of the 
tablets of the two types of gums (locust & guar) corresponding to 
formulas M4 and M5 were compared, the similarity ƒ2 value was 
found to be 60, indicating that the two profiles were similar. Keeping 
in mind that these two gums gave similar floating properties as well, 
it can be predicted that these two gums can be alternatively used to 
prepare MZ floating tablets. 
It is established that in controlled or sustained release formulations, 
diffusion, swelling and erosion are the three most important rate 
controlling mechanisms [25]. For formulas M1 (HPMC-K4M) and M4 
(Locust gum) drug release rate gave a biphasic release rate pattern. 
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The rapid phase showed in the initial 15 min of the release study 
and followed by a slower one.  
 
 
Fig. 2: Release profiles of MZ from different floating tablet 
formulas.  
 
Table 3: Percentage of MZ released after 6 h (Q6h) and a 
comparison between release profiles of natural polymers and 
HPMC-K4M (set as reference) by the similarity factor method (f2). 
Formula Q6h (% ± SD)  similarity factor (f2) 
M1 (HPMC-K4M) 61.26 ± 0.91  _ 
M2 (Na alginate - MV) 43.42 ± 2.52  39 
M3 (Na alginate - LV) 75.11 ± 3.66  50 
M4 (Locust gum) 54.25 ± 2.71  51 
M5 (Guar gum) 54.56 ± 2.54  63 
 
The release kinetics was computed by fitting the release rate data to 
zero-order, first-order, second-order, Higuchi, and Hixson & Crowell 
cube root models [Eqs. (2-6)]. The drug release rates from MZ 
formulas were found to follow either zero-order kinetics, Eq. (2) 
(M2, and M5), i.e. MZ release rate was independent of its 
concentration [59] or Hixson-Crowell cube root model, Eq. (6) (M1 
and M4), explaining that the release of the drug from these systems 
depended on the change in surface area and diameter of the tablets 
with time which is a typical case of systems that dissolute or erode 
over time. Only formula M3 followed the first order release kinetics, 
Eq. (3), meaning that the release rate is concentration-dependent 
[59]. The t1/2 values of the prepared floating tablets were in the 
range of 4.25 h - 6.76 h (Table 4). Formula M1 showed the lowest 
value of t1/2, while formula M2 exhibited the highest value. 
Table 4: The kinetic release models obtained from the release data and the corresponding t1/2 values. 
Formula Code Release model *t1/2 (h)  
M1 Hixson and Crowell Cube-Root 4.25  
M2 Zero-Order 6.76  
M3 First order 3.03  
M4 Hixson and Crowell Cube-Root 5.29  
M5 Zero-Order 5.70  
 *Where half-life (t1/2) is the time required to reduce the drug concentration to one half its initial value [61,62]. 
 
DSC analysis results 
The possibility of occurrence of any drug - excipients interactions in 
the tablets was predicted by conducting DSC studies [70]. Fig. 3 
showed the DSC thermograms of MZ, polymers and MZ floating 
tablet formulations. A sharp endothermic peak corresponding to the 
melting point of pure drug MZ was found at 166 ºC. For drug sample 
and the proposed formulations, the thermograms did not show any 
significant shift in endothermic peaks. Based on the thermograms of 
DSC, there is no possibility of interactions between MZ and the 
proposed excipients. These systems will be subjected to a long-term 
stability study to give a full data about the feasibility of selecting the 
optimum formula.  
 
 
Fig. 3: DSC thermograms of MZ, polymers and MZ floating tablet 
formulations. 
FT-IR analysis results 
The FT-IR spectra analysis of MZ and the physical mixtures revealed 
that there was no significant interaction between drug and polymers 
as shown in Fig. 4. The characteristic band peaks acquired were 
taken from the prepared drug-polymer mixtures. The interaction 
study between drug and polymer was evaluated [71].  
 
 
Fig. 4: FT-IR spectra of MZ, polymers and MZ floating tablet 
formulations. 
 
The FT-IR spectra of the physical mixture of the drug with polymers 
exhibited all the characteristic bands as in the spectrum of the 
individual MZ, HPMC, Na alginates, Locust gum and Guar gum and 
other excipients excluding the possibility of any interaction. Also, 
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chemical and functional group changes during the processing of the 
formulation of floating tablets were excluded [72].  
CONCLUSIONS 
The present study demonstrates the feasibility of prolonging the 
gastric residence time of anti- H. pylori drugs via oral administration 
of the proposed floating tablets. Sustained release of metronidazole 
(MZ) from such floating tablets can be achieved over a period of at 
least 6 h. Additionally, the study proposed that Na alginate-LV and 
two gums (locust and guar) could be used as an alternative to the 
widely used synthetic polymer HPMC-K4M for formulating floating 
tablets containing 250 mg MZ. This would be an advantage as 
natural polymers are safe, nontoxic, capable of chemical 
modification and have gel forming nature. Also, they are 
biocompatible, inexpensive and readily available compared to 
synthetic polymers. These dosage forms need further 
phsicochemical stability studies as well as a clinical trial involving 
patients suffering from peptic ulcer. These stomach targeted dosage 
forms could maintain the minimum inhibitory concentration for 
sufficient time to allow for local eradication and thereby achieve 
better efficiency of therapy with improved patient compliance, 
reduced costs and minimized side effects caused by immediate 
release dosage forms.  
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